July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Lycium Barbarum Polysaccharides as a Potential New therapy to Prevent Corneal Scarring
Author Affiliations & Notes
  • Sum Sum Kwok
    Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong
  • Francisca SY Wong
    Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong
  • Amy CY Lo
    Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong
  • Yau Kei Chan
    Mechanical Engineering, The University of Hong Kong, Hong Kong
  • Tommy Chun-Yan Chan
    Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong
  • Kendrick Co Shih
    Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong
  • Footnotes
    Commercial Relationships   Sum Sum Kwok, None; Francisca SY Wong, None; Amy Lo, None; Yau Kei Chan, None; Tommy Chun-Yan Chan, None; Kendrick Shih, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4659. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sum Sum Kwok, Francisca SY Wong, Amy CY Lo, Yau Kei Chan, Tommy Chun-Yan Chan, Kendrick Co Shih; Lycium Barbarum Polysaccharides as a Potential New therapy to Prevent Corneal Scarring. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4659. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To the efficacy and optimal concentration of Lycium barbarum polysaccharide (LBP) solution in the suppression of keratocyte myofibroblast-differentiation and proliferation in an in vitro model of cornea epithelial-stromal injury.

Methods : Cell culture and characterization - Primary human corneal keratocytes were used and cultured using fibroblast medium supplemented with 2% FBS, fibroblast growth supplement and penicillin/streptomycin. Cells were characterized through fibroblast-like morphology, vimentin and fibronectin staining. Passage 4 to 6 cells were used for experiments.
Myofibroblast differentiation and fibrotic protein expression- Cells were first pre-treated with LBP for 24 hours then 10ng/ml TGFB1 for 48 hours. Myofibroblast-differentiation was assessed through α-smooth muscle actin immunofluorescence (IF) staining and further quantified by western blot. Presence of type I, II and III collagen are assessed using IF.
Scratch wound assay - Keratocytes were pretreated with LBP medium. Upon confluency, the monolayer of keratocytes was wounded with a plastic micropipette tip and the rate of wound closure was determined using time-lapse microscopy.
Proliferation Assay - Keratocytes were seeded onto 48-well plates, pre-treated with specific LBP concentrations for 24 hours then TGFB1 induction at 10ng/ml for 48 hours. The number of viable cells was estimated using the MTS assay.

Results : Characteristic morphology and positive staining for vimentin and fibronectin were identified in our human keratocyte cell line using phase-contrast microscopy and IF microscopy respectively. Under IF, using α-smooth muscle actin staining, we demonstrated that LBP pre-treatment effectively inhibited keratocyte myofibroblast-differentiation in a dose-dependent fashion. With the cell viability assay, we further demonstrated that higher LBP concentrations selectively inhibited myofibroblast proliferation but had no significant effect of keratocyte proliferation.

Conclusions : Lycium barbarum polysaccharides is a promising therapeutic agent that selectively inhibits myofibroblast differentiation and proliferation after corneal injury. This potentially attenuates corneal scarring by reducing myofibroblast extracellular matrix secretion without inhibiting keratocyte activity, which plays an important role in corneal innate immunity.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×